首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Comparative study of 25 μg vaginal misoprostol v/s cerviprime gel for induction of labour at term
【24h】

Comparative study of 25 μg vaginal misoprostol v/s cerviprime gel for induction of labour at term

机译:25μg阴道米索前列醇v / s cerviprime凝胶在足月引产的比较研究

获取原文
           

摘要

Background: This comparative study was conducted to compare the effectiveness of 25 μg of intravaginal misoprostol with intracervical cerviprime gel in terms of efficacy of drug, foeto-maternal outcome, side effects and complications of drugs. Methods: 100 primigravida at term; who were admitted for induction of labour were included in this study. They were randomly selected to receive either intravaginal misoprostol or intracervical cerviprime gel. 50 women received intravaginal 25 μg Misoprostol (Group A) every 6 hours for maximum of 5 doses and 50 women received 0.5 mg (2.5 ml) of intracervical cerviprime gel (Group B) till maximum of 3 doses. Comparison was done in terms of time taken for induction to delivery, mean time taken for onset of labour, APGAR score at 1 and 5 minutes and the neonatal outcome in either of the groups. Results: The mean time taken for onset of labour was less in the misoprostol group than in the cerviprime group (6.5 hours v/s 8 hours, P = 0.49). Similarly duration from induction to delivery was less (20.08 ± 8.24 hours v/s 23.19 ± 9.59 hours, P >0.05) for misoprostol than cerviprime gel. Need for Oxytocin augmentation was less (16%) in misoprostol group as compared to cerviprime group (46%), P = 0.001. Cesarean section rate was slightly higher in misoprostol group (8% v/s 6%). Maternal complications were minimal in either group & the neonatal outcome was good in both the groups. The induction cost was much less in the misoprostol group. Conclusions: Compared to cerviprime gel; misoprostol is safe, efficacious, cheap, well tolerated drug by mother and fetus. It was found to be a better inducing agent, has short induction to delivery interval thus short duration of labour with similar maternal and fetal safety profile.
机译:背景:这项比较研究旨在比较25μg阴道内米索前列醇和宫颈内头皮凝胶剂在药物效力,母体预后,副作用和药物并发症方面的功效。方法:足月妊娠100例;本研究包括因引产而入院的人。他们被随机选择接受阴道内米索前列醇或宫颈宫颈初乳凝胶治疗。每6小时有50名妇女接受阴道内25μg米索前列醇(A组)最多5剂,而50名妇女接受0.5 mg(2.5 ml)的宫颈宫颈内分泌凝胶(B组)直到最多3剂。比较两组间诱导分娩所需的时间,分娩开始的平均时间,1分钟和5分钟时的APGAR评分以及新生儿结局。结果:米索前列醇组的平均分娩时间少于头孢普列组(6.5小时v / s 8小时,P = 0.49)。同样,米索前列醇从诱导到分娩的持续时间比cerviprime凝胶短(20.08±8.24小时v / s 23.19±9.59小时,P> 0.05)。米索前列醇组催产素增加的需求少于头孢普列组(46%)(P = 0.001)。米索前列醇组剖宫产率略高(8%v / s 6%)。两组的产妇并发症最少,两组的新生儿结局均良好。米索前列醇组的诱导成本要低得多。结论:与cerviprime凝胶相比;米索前列醇对母亲和胎儿是安全,有效,便宜,耐受性良好的药物。人们发现它是一种更好的诱导剂,对分娩间隔的诱导时间短,因此产妇和胎儿安全状况相似的分娩时间短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号